Molecular landscape and clinical outcome of / Co-mutated myeloid neoplasms.

The mutations in and genes are frequently present in various myeloid neoplasms. The potential impact of / co-mutations on patient survival is incompletely understood. We identified 412 patients with / co-mutations from our NextGen sequencing database of around 8000 patients and reported likely the largest cohort study. Our study demonstrated the presence of these co-mutations in a spectrum of myeloid neoplasms, which show different genetic and molecular characteristics. Most of the patients with these co-mutations had normal karyotype. Interestingly, our study provided insights into the prevalence of additional mutations such as , , and with this co-mutation and their potential impact on patients' prognosis. We found that , , and can negatively impact these patients' survival with different impacts in different morphological diagnosis categories, suggesting a complex interaction between these genes. This study underscores the need for personalized approaches in the treatment of myeloid neoplasms.